Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 372 entries
Sorted by: Best Match Show Resources per page
B-type natriuretic peptides (BNP and PRO-BNP) predict longterm survival in patients with advanced heart failure treated with atenolol.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

Berger R, Stanek B, Frey B, Sturm B, Huelsmann M, Bergler-Klein J, Pacher R.
PMID: 11250499
J Heart Lung Transplant. 2001 Feb;20(2):251. doi: 10.1016/s1053-2498(00)00571-4.

No abstract available.

Cite
Berger R, Stanek B, Frey B, et al. B-type natriuretic peptides (BNP and PRO-BNP) predict longterm survival in patients with advanced heart failure treated with atenolol. J Heart Lung Transplant. 2001;20(2):251doi: 10.1016/s1053-2498(00)00571-4.
Berger, R., Stanek, B., Frey, B., Sturm, B., Huelsmann, M., Bergler-Klein, J., & Pacher, R. (2001). B-type natriuretic peptides (BNP and PRO-BNP) predict longterm survival in patients with advanced heart failure treated with atenolol. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 20(2), 251. https://doi.org/10.1016/s1053-2498(00)00571-4
Berger, R, et al. "B-type natriuretic peptides (BNP and PRO-BNP) predict longterm survival in patients with advanced heart failure treated with atenolol." The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation vol. 20,2 (2001): 251. doi: https://doi.org/10.1016/s1053-2498(00)00571-4
Berger R, Stanek B, Frey B, Sturm B, Huelsmann M, Bergler-Klein J, Pacher R. B-type natriuretic peptides (BNP and PRO-BNP) predict longterm survival in patients with advanced heart failure treated with atenolol. J Heart Lung Transplant. 2001 Feb;20(2):251. doi: 10.1016/s1053-2498(00)00571-4. PMID: 11250499.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 11980386
Methods Find Exp Clin Pharmacol. 2002 Jan-Feb;24(1):37-55.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses, which has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the world's first drug discovery and development...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002;24(1):37-55
Bayes, M., Rabasseda, X., & Prous, J. R. (2002). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 24(1), 37-55.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 24,1 (2002): 37-55.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Jan-Feb;24(1):37-55. PMID: 11980386.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 12616965
Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002;24(10):703-29
Bayés, M., Rabasseda, X., & Prous, J. R. (2002). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 24(10), 703-29.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 24,10 (2002): 703-29.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29. PMID: 12616965.
Copy Download .nbib Format: NLM
Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol.

Clinical drug investigation

Seedat YK, Randeree IG.
PMID: 18370544
Clin Drug Investig. 1998;16(3):229-40. doi: 10.2165/00044011-199816030-00007.

OBJECTIVE: This study compared the antihypertensive effect and acceptability of a perindopril-based group with that of an atenolol-based group in Indian hypertensive type 2 (non-insulin-dependent) diabetic patients.DESIGN AND SETTING: 100 ambulant patients aged between 35 and 69 years were...

Cite
Seedat YK, Randeree IG. Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol. Clin Drug Investig. 1998;16(3):229-40doi: 10.2165/00044011-199816030-00007.
Seedat, Y. K., & Randeree, I. G. (1998). Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol. Clinical drug investigation, 16(3), 229-40. https://doi.org/10.2165/00044011-199816030-00007
Seedat, Y K, and Randeree, I G. "Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol." Clinical drug investigation vol. 16,3 (1998): 229-40. doi: https://doi.org/10.2165/00044011-199816030-00007
Seedat YK, Randeree IG. Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol. Clin Drug Investig. 1998;16(3):229-40. doi: 10.2165/00044011-199816030-00007. PMID: 18370544.
Copy Download .nbib Format: NLM
Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension.

Evidence-based medicine

Zarnke KB.
PMID: 17213072
Evid Based Med. 2006 Apr;11(2):42. doi: 10.1136/ebm.11.2.42.

No abstract available.

Cite
Zarnke KB. Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension. Evid Based Med. 2006;11(2):42doi: 10.1136/ebm.11.2.42.
Zarnke, K. B. (2006). Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension. Evidence-based medicine, 11(2), 42. https://doi.org/10.1136/ebm.11.2.42
Zarnke, Kelly B. "Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension." Evidence-based medicine vol. 11,2 (2006): 42. doi: https://doi.org/10.1136/ebm.11.2.42
Zarnke KB. Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension. Evid Based Med. 2006 Apr;11(2):42. doi: 10.1136/ebm.11.2.42. PMID: 17213072.
Copy Download .nbib Format: NLM
A simple method for the study of salbutamol pharmacokinetics by ion chromatography with direct conductivity detection.

Talanta

Ouyang J, Duan JL, Baeyens WR, Delanghe JR.
PMID: 18969756
Talanta. 2005 Jan 15;65(1):1-6. doi: 10.1016/j.talanta.2004.01.026.

A simple method for the study of the pharmacokinetics of salbutamol using ion chromatography with direct conductivity detection without chemical suppression is presented in this paper. Baseline separation of salbutamol from plasma components was achieved by using diluted HNO(3)...

Cite
Ouyang J, Duan JL, Baeyens WR, et al. A simple method for the study of salbutamol pharmacokinetics by ion chromatography with direct conductivity detection. Talanta. 2005;65(1):1-6doi: 10.1016/j.talanta.2004.01.026.
Ouyang, J., Duan, J. L., Baeyens, W. R., & Delanghe, J. R. (2005). A simple method for the study of salbutamol pharmacokinetics by ion chromatography with direct conductivity detection. Talanta, 65(1), 1-6. https://doi.org/10.1016/j.talanta.2004.01.026
Ouyang, Jin, et al. "A simple method for the study of salbutamol pharmacokinetics by ion chromatography with direct conductivity detection." Talanta vol. 65,1 (2005): 1-6. doi: https://doi.org/10.1016/j.talanta.2004.01.026
Ouyang J, Duan JL, Baeyens WR, Delanghe JR. A simple method for the study of salbutamol pharmacokinetics by ion chromatography with direct conductivity detection. Talanta. 2005 Jan 15;65(1):1-6. doi: 10.1016/j.talanta.2004.01.026. PMID: 18969756.
Copy Download .nbib Format: NLM
Trial finds verapamil and atenolol-based antihypertensive regimens are similarly effective in coronary artery disease.

Evidence-based cardiovascular medicine

[No authors listed]
PMID: 16379913
Evid Based Cardiovasc Med. 2004 Jun;8(2):127-8; discussion 129-30. doi: 10.1016/j.ebcm.2004.03.009.

No abstract available.

Cite
Trial finds verapamil and atenolol-based antihypertensive regimens are similarly effective in coronary artery disease. Evid Based Cardiovasc Med. 2004;8(2):127-8; discussion 129-30doi: 10.1016/j.ebcm.2004.03.009.
(2004). Trial finds verapamil and atenolol-based antihypertensive regimens are similarly effective in coronary artery disease. Evidence-based cardiovascular medicine, 8(2), 127-8; discussion 129-30. https://doi.org/10.1016/j.ebcm.2004.03.009
"Trial finds verapamil and atenolol-based antihypertensive regimens are similarly effective in coronary artery disease." Evidence-based cardiovascular medicine vol. 8,2 (2004): 127-8; discussion 129-30. doi: https://doi.org/10.1016/j.ebcm.2004.03.009
Trial finds verapamil and atenolol-based antihypertensive regimens are similarly effective in coronary artery disease. Evid Based Cardiovasc Med. 2004 Jun;8(2):127-8; discussion 129-30. doi: 10.1016/j.ebcm.2004.03.009. PMID: 16379913.
Copy Download .nbib Format: NLM
Atenolol is less effective than other antihypertensive drugs. Commentary 2.

Evidence-based cardiovascular medicine

Burns J.
PMID: 16392160
Evid Based Cardiovasc Med. 2005 Mar;9(1):11, 14. doi: 10.1016/j.ebcm.2005.01.005.

No abstract available.

Cite
Burns J. Atenolol is less effective than other antihypertensive drugs. Commentary 2. Evid Based Cardiovasc Med. 2005;9(1):11, 14doi: 10.1016/j.ebcm.2005.01.005.
Burns, J. (2005). Atenolol is less effective than other antihypertensive drugs. Commentary 2. Evidence-based cardiovascular medicine, 9(1), 11, 14. https://doi.org/10.1016/j.ebcm.2005.01.005
Burns, Joanna. "Atenolol is less effective than other antihypertensive drugs. Commentary 2." Evidence-based cardiovascular medicine vol. 9,1 (2005): 11, 14. doi: https://doi.org/10.1016/j.ebcm.2005.01.005
Burns J. Atenolol is less effective than other antihypertensive drugs. Commentary 2. Evid Based Cardiovasc Med. 2005 Mar;9(1):11, 14. doi: 10.1016/j.ebcm.2005.01.005. PMID: 16392160.
Copy Download .nbib Format: NLM
Antiaggregatory Properties of Beta-adrenoceptor Blocking Drugs are Related to their Physico-chemical Properties.

Platelets

Nosál R, Jancinová V, Petriková M.
PMID: 21043897
Platelets. 1992;3(1):29-33. doi: 10.3109/09537109209013165.

The effects of the beta-adrenoceptor blockers (BAB) alprenolol, atenolol, metipranolol, oxprenolol, practolol and propranolol on platelet aggregation stimulated by ADP, thrombin and collagen were investigated. The BAB were divided into three groups according to their liposolubility and antiaggregatory activity....

Cite
Nosál R, Jancinová V, Petriková M. Antiaggregatory Properties of Beta-adrenoceptor Blocking Drugs are Related to their Physico-chemical Properties. Platelets. 1992;3(1):29-33doi: 10.3109/09537109209013165.
Nosál, R., Jancinová, V., & Petriková, M. (1992). Antiaggregatory Properties of Beta-adrenoceptor Blocking Drugs are Related to their Physico-chemical Properties. Platelets, 3(1), 29-33. https://doi.org/10.3109/09537109209013165
Nosál, R, et al. "Antiaggregatory Properties of Beta-adrenoceptor Blocking Drugs are Related to their Physico-chemical Properties." Platelets vol. 3,1 (1992): 29-33. doi: https://doi.org/10.3109/09537109209013165
Nosál R, Jancinová V, Petriková M. Antiaggregatory Properties of Beta-adrenoceptor Blocking Drugs are Related to their Physico-chemical Properties. Platelets. 1992;3(1):29-33. doi: 10.3109/09537109209013165. PMID: 21043897.
Copy Download .nbib Format: NLM
Sodium Transport in Human Platelets as an Index of Na,K-ATPase Activity.

Platelets

Ozin RL, Mikhailidis DP, Baron DN.
PMID: 21043909
Platelets. 1992;3(3):163-9. doi: 10.3109/09537109209013177.

Both sodium ((22)Na) and rubidium ((86)Rb) influx, an index of potassium transport, were studied in human platelets to establish a simple and rapid method for the study of the sodium pump in platelets. (22)Na was taken up by platelets...

Cite
Ozin RL, Mikhailidis DP, Baron DN. Sodium Transport in Human Platelets as an Index of Na,K-ATPase Activity. Platelets. 1992;3(3):163-9doi: 10.3109/09537109209013177.
Ozin, R. L., Mikhailidis, D. P., & Baron, D. N. (1992). Sodium Transport in Human Platelets as an Index of Na,K-ATPase Activity. Platelets, 3(3), 163-9. https://doi.org/10.3109/09537109209013177
Ozin, R L, et al. "Sodium Transport in Human Platelets as an Index of Na,K-ATPase Activity." Platelets vol. 3,3 (1992): 163-9. doi: https://doi.org/10.3109/09537109209013177
Ozin RL, Mikhailidis DP, Baron DN. Sodium Transport in Human Platelets as an Index of Na,K-ATPase Activity. Platelets. 1992;3(3):163-9. doi: 10.3109/09537109209013177. PMID: 21043909.
Copy Download .nbib Format: NLM
Ivabradine: the evidence of its therapeutic impact in angina.

Core evidence

Marquis-Gravel G, Tardif JC.
PMID: 20694080
Core Evid. 2008 Jun;3(1):1-12. doi: 10.3355/ce.2008.008.

INTRODUCTION: Stable angina pectoris (SAP) is a widely prevalent disease affecting 30 000 to 40 000 per million people in Europe and the US. SAP is associated with reductions in quality of life and ability to work, and increased...

Cite
Marquis-Gravel G, Tardif JC. Ivabradine: the evidence of its therapeutic impact in angina. Core Evid. 2008;3(1):1-12doi: 10.3355/ce.2008.008.
Marquis-Gravel, G., & Tardif, J. C. (2008). Ivabradine: the evidence of its therapeutic impact in angina. Core evidence, 3(1), 1-12. https://doi.org/10.3355/ce.2008.008
Marquis-Gravel, Guillaume, and Tardif, Jean-Claude. "Ivabradine: the evidence of its therapeutic impact in angina." Core evidence vol. 3,1 (2008): 1-12. doi: https://doi.org/10.3355/ce.2008.008
Marquis-Gravel G, Tardif JC. Ivabradine: the evidence of its therapeutic impact in angina. Core Evid. 2008 Jun;3(1):1-12. doi: 10.3355/ce.2008.008. PMID: 20694080; PMCID: PMC2899802.
Copy Download .nbib Format: NLM
Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension.

Indian journal of pharmacology

Badar VA, Hiware SK, Shrivastava MP, Thawani VR, Hardas MM.
PMID: 21845001
Indian J Pharmacol. 2011 Jul;43(4):437-40. doi: 10.4103/0253-7613.83117.

BACKGROUND: Nebivolol is a third-generation β-blocker, with highest β(1) selectivity and nitric-oxide-derived vasodilatation. It also exhibits antiproliferative and antioxidant property that has beneficial metabolic profile compared to second-generation β blockers like atenolol. This study was planned to study the...

Cite
Badar VA, Hiware SK, Shrivastava MP, et al. Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension. Indian J Pharmacol. 2011;43(4):437-40doi: 10.4103/0253-7613.83117.
Badar, V. A., Hiware, S. K., Shrivastava, M. P., Thawani, V. R., & Hardas, M. M. (2011). Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension. Indian journal of pharmacology, 43(4), 437-40. https://doi.org/10.4103/0253-7613.83117
Badar, V A, et al. "Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension." Indian journal of pharmacology vol. 43,4 (2011): 437-40. doi: https://doi.org/10.4103/0253-7613.83117
Badar VA, Hiware SK, Shrivastava MP, Thawani VR, Hardas MM. Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension. Indian J Pharmacol. 2011 Jul;43(4):437-40. doi: 10.4103/0253-7613.83117. PMID: 21845001; PMCID: PMC3153709.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 372 entries